Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
Gastric Cancer|Perioperative|Sintilimab
DRUG: Sintilimab|DRUG: S-1|DRUG: Oxaliplatin
Pathological complete response (pCR) rate, Pathological complete response (pCR) rate is defined as the proportion of participants whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist., up to 8 weeks after surgery
Tumor down-staging rate, Tumor down-staging is defined as any stage reduction between clinical and pathologic stage, up to 8 weeks after surgery|Major pathological response (MPR) rate, Major pathological response (MPR) rate is defined as the proportion of participants whose percentage of residual tumor in the stomach and lymph node decreased to \< 10%, as determined by a pathologist., up to 8 weeks after surgery|3 years disease-free survival (DFS) rate, 3 years disease-free survival (DFS) rate is defined as proportion of participants who have no recurrence or metastasis after 3 years of radical treatment, up to 4 years|5 years overall survival (OS) rate, 5 years overall survival (OS) rate is defined as proportion of participants who survived 5 years after radical treatment, up to 6 years|Adverse event, All grades of adverse events, all grades of treatment related adverse events, serious of adverse events, up to 30 days after last treatment administration|Overall response rate ( ORR), Overall response rate ( ORR) is defined as proportion of participants who have a best response of CR or PR, up to 30 days after last preoperative treatment administration|Disease Control Rate (DCR), Disease Control Rate (DCR) is defined as proportion of participants who have a best response of CRã€PR or SD, up to 30 days after last preoperative treatment administration
To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma